Navigation Links
Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
Date:12/10/2007

Preliminary results demonstrate patients with chronic idiopathic thrombocytopenic purpura increased and maintained platelet counts at greater than or equal to 50,000/microliters with extended treatment

ATLANTA, Dec. 10 /PRNewswire-USNewswire/ -- GlaxoSmithKline today announced data on the long-term safety and efficacy of its investigational drug PROMACTA(TM) (eltrombopag) for the treatment of chronic idiopathic thrombocytopenic purpura (ITP).(1) These preliminary results from the EXTEND (Eltrombopag eXTENded Dosing) study showed that of the patients with a baseline platelet count of less than 30,000/microliters, 73% achieved a platelet count of greater than or equal to 50,000/microliters. The average treatment period for all patients, from this ongoing treatment study, has lasted almost 22 weeks (five months) so far. These results suggest that PROMACTA sustains increased platelet counts during long-term treatment.(1) This research was presented at the 49th Annual Meeting of the American Society of Hematology, December 8-11 2007 in Atlanta, GA.

PROMACTA is an investigational compound that has not received regulatory approval in any market for any indication at this time.

PROMACTA was generally well tolerated in this study. Of the 94 patients who received at least one dose of PROMACTA, 83% reported at least one adverse event (AE), 32% reported a drug-related AE and 13% reported a serious AE (SAE). Most AEs were mild in severity with the most common being headache (20%).(1)

Chronic ITP is a disorder characterized by low levels of platelets in the blood, with patients suffering from excessive bruising and bleeding and in some cases having serious hemorrhages that can be fatal.(2,3,4) An estimated 200,000 individuals are diagnosed with ITP in the U.S.(5) and a similar number in Europe. PROMACTA is an investigational oral, non-peptide, platelet growth factor that induces the proliferation and differentiation of cells in the bone
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...EO, Calif., Sept. 4 /- BioF... that the pivotal clinical study of,Polidocanol, c...Chemische,Fabrik KREUSSLER & Co. GmbH (Kreussler),...as been submitted to FDA as part of a New Drug App...study, named the EASI (Efficacy and safety of,Aeth...
(Date:9/4/2008)...a Published in ,The Lancet, and Presented at ESC C...esults from a new international,study, the GISSI H...ose of,omega-3 acid ethyl esters reduced all cause...lar reasons in patients with chronic heart,failure...ne version of ,The,Lancet, and were presented at t...
(Date:9/4/2008)...HAM, Ala., Sept. 4 /- Southern Resear...titutes of Health (NIH) has selected,the organizat...ibraries,Probe Production Center Network (MLPCN). ...s part of the Molecular Libraries Program which is...fic knowledge of the human,genome and validate fut...
(Date:9/4/2008)... Switzerland, September 4 /- Axentis ... to assess the safety and tolerability,of a new th...pulmonary,infection in cystic fibrosis patients. T...ic agent to be delivered directly to the site of,i...the effects of two,different doses of the new drug...
Breaking Medicine Technology:338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4UK government has reneged on pledge for flexible working in NHS 5992 1UK government has reneged on pledge for flexible working in NHS 5992 2Researchers successfully simulate photosynthesis and design a better leaf 1169 1Researchers successfully simulate photosynthesis and design a better leaf 1169 2Researchers successfully simulate photosynthesis and design a better leaf 1169 3Abnormal immune cells may cause unprovoked anaphylaxis 5990 1Abnormal immune cells may cause unprovoked anaphylaxis 5990 2Abnormal immune cells may cause unprovoked anaphylaxis 5990 3Research highlights important indicators of early stage ovarian cancer 5988 1
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...ldrens Hospital Medical Center study shows that a ...obese teens when run by pediatricians in the offi...ting of the Pediatric Academic Societies in Toront...s who completed the six-month study lost weight, a...
...the controversial icon of the right is no more . ...jority and used it to mold the religious right int...ing found unconscious in his office at Liberty Uni...died suddenly of what his doctor suspects was the ...
...s bad tidings for those heavy-handed on multivitam...s National Cancer Institute , reveals that those w...k, can in fact increase their risk of contracting ...r. The researchers who published their work in ...
... the number of urban parks and street trees in our...mperature rise, a new study by researchers from t...ng to the team, a mere 10 percent increase in the ...ntres would reduce urban surface temperatures by a...
Other Medicine News:Health News:Low-Carb Diet Effective for Teens Trying to Lose Weight 2Health News:Extremist Christian Preacher Dies of Heart Problems 2Health News:Being Overzealous With Multivitamins May Lead To Prostate Cancer 2Health News:Modest Increase in Urban Parks Could Equalize Global Warming Until 2080s 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device.
Clinicians are demanding smaller, higher performing systems specifically designed to meet their clinical and operational challenges. The new Philips HD11 XE system provides a powerful architecture fo
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea
InfinixTM CF-i/SP brings revolutionary flexibility to floor-mounted X-ray systems. The unique design enables operators to move the C-arm around the exam table as needed to obtain the optimal angle fo
Medicine Products: